Webinar

Strengthening Your Supply Chain: The Power of Dual Sourcing Pharmaceutical Packaging

This on-demand webinar delivers a strategic and operational framework for pharmaceutical packaging professionals evaluating dual sourcing of container closure components — covering the risk categories that make single-source dependency dangerous, the practical steps to qualify a secondary supplier without disrupting compliance, and how a toolkit-based qualification approach simplifies the process across multiple drug products.

Status Published

Format Webinar

Language English

Access Registration Required

Watch the Webinar

Resource Overview

About this Webinar

In today's unpredictable pharmaceutical supply chain landscape, single-source dependency for critical parenteral packaging components is an operational vulnerability that COVID-19 exposed with clarity — and that ongoing geopolitical instability, tariff uncertainty, and persistent drug shortages continue to reinforce. This on-demand webinar provides pharmaceutical packaging, procurement, quality, and regulatory professionals with a structured framework for understanding, evaluating, and implementing dual sourcing for injectable drug packaging components. The session covers the root causes and lasting effects of pandemic-driven supply disruptions; the specific risk categories — financial, operational, regulatory, and human factor — that make sourcing diversification a strategic imperative rather than a contingency measure; a practical, step-by-step approach to qualifying a secondary aluminum seal or elastomeric closure supplier against material compatibility, machinability, container closure integrity (CCI), residual seal force (RSF), sterility format (RTU/RFS/RTP), and regulatory compliance criteria; the toolkit qualification model that simplifies dual sourcing across multi-product portfolios; and how proactive qualification — completed before a supply disruption occurs — is substantially less costly and disruptive than emergency qualification under active shortage conditions.

With post-COVID lead times still elevated and 368 drugs on active shortage lists, proactive dual sourcing qualification before a supply disruption is substantially more cost-effective than emergency qualification under active shortage conditions — making the business case for second-source investment compelling across virtually every parenteral drug program.
Qualifying a secondary packaging supplier requires systematic evaluation of material compliance per ISO 9001/15378, machinability on high-speed fill-finish lines, CCI and RSF equivalence, sterility format availability (RTU/RFS/RTP), and multi-site regional manufacturing — with plug-and-play compatibility (no equipment modification required) as the critical functional gate.
A toolkit approach — qualifying platform-compatible components across multiple drug products simultaneously — maximizes dual sourcing investment by reducing per-product qualification burden and creating inherent supply chain flexibility that can be deployed across programs without additional qualification work when a disruption occurs.

Watch the Webinar